Leadership transition for AusCann

Company News

by Rachael Jones

Leading medical cannabis company AusCann Group Holdings (ASX:AC8) has appointed experienced pharmaceutical executive, Dr Paul MacLeman, to the AusCann Board as an Executive Director.

Dr MacLeman has over 25 years’ board and executive experience across the life sciences, agricultural and not for profit sectors.

He has launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking.

Elaine Darby has informed the Board of her intention to step down as Managing Director.

AusCann is transitioning from a start-up company focused on licensing and product development, to a pharmaceutical production and sales business.

Shares in AusCann Group Holdings (ASX:AC8) are trading 3.03 per cent higher to $1.02.


Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.